{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:35:25Z","timestamp":1783956925304,"version":"3.55.0"},"reference-count":72,"publisher":"National Institute for Health and Care Research","issue":"50","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["13\/142\/04"],"award-info":[{"award-number":["13\/142\/04"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"published-print":{"date-parts":[[2022,12]]},"abstract":"Background<\/jats:title>The National Institute for Health and Care Excellence recommends macular laser to treat diabetic macular oedema with a central retinal subfield thickness of <\u2009400\u2009\u00b5m on optical coherence tomography. The DIAMONDS (DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser) trial compared standard threshold macular laser with subthreshold micropulse laser to treat diabetic macular oedema suitable for macular laser.<\/jats:p><\/jats:sec>Objectives<\/jats:title>Determining the clinical effectiveness, safety and cost-effectiveness of subthreshold micropulse laser compared with standard threshold macular laser to treat diabetic macular oedema with a central retinal subfield thickness of <\u2009400\u2009\u00b5m.<\/jats:p><\/jats:sec>Design<\/jats:title>A pragmatic, multicentre, allocation-concealed, double-masked, randomised, non-inferiority, clinical trial.<\/jats:p><\/jats:sec>Setting<\/jats:title>Hospital eye services in the UK.<\/jats:p><\/jats:sec>Participants<\/jats:title>Adults with diabetes and centre-involving diabetic macular oedema with a central retinal subfield thickness of <\u2009400\u2009\u00b5m, and a visual acuity of >\u200924 Early Treatment Diabetic Retinopathy Study letters (Snellen equivalent >\u200920\/320) in one\/both eyes.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomised 1\u2009:\u20091 to receive 577\u2009nm subthreshold micropulse laser or standard threshold macular laser (e.g. argon laser, frequency-doubled neodymium-doped yttrium aluminium garnet 532\u2009nm laser); laser treatments could be repeated as needed. Rescue therapy with intravitreal anti-vascular endothelial growth factor therapies or steroids was allowed if a loss of \u2265\u200910 Early Treatment Diabetic Retinopathy Study letters between visits occurred and\/or central retinal subfield thickness increased to >\u2009400\u2009\u00b5m.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>The primary outcome was the mean change in best-corrected visual acuity in the study eye at 24 months (non-inferiority margin 5 Early Treatment Diabetic Retinopathy Study letters). Secondary outcomes included the mean change from baseline to 24 months in the following: binocular best-corrected visual acuity; central retinal subfield thickness; the mean deviation of the Humphrey 10\u20132 visual field in the study eye; the percentage of people meeting driving standards; and the EuroQol-5 Dimensions, five-level version, National Eye Institute Visual Function Questionnaire \u2013 25 and Vision and Quality of Life Index scores. Other secondary outcomes were the cost per quality-adjusted life-years gained, adverse effects, number of laser treatments and additional rescue treatments.<\/jats:p><\/jats:sec>Results<\/jats:title>The DIAMONDS trial recruited fully (n<\/jats:italic>\u2009=\u2009266); 87% of participants in the subthreshold micropulse laser group and 86% of participants in the standard threshold macular laser group had primary outcome data. Groups were balanced regarding baseline characteristics. Mean best-corrected visual acuity change in the study eye from baseline to month 24 was \u20132.43 letters (standard deviation 8.20 letters) in the subthreshold micropulse laser group and \u20130.45 letters (standard deviation 6.72 letters) in the standard threshold macular laser group. Subthreshold micropulse laser was deemed to be not only non-inferior but also equivalent to standard threshold macular laser as the 95% confidence interval (\u20133.9 to \u20130.04 letters) lay wholly within both the upper and lower margins of the permitted maximum difference (5 Early Treatment Diabetic Retinopathy Study letters). There was no statistically significant difference between groups in any of the secondary outcomes investigated with the exception of the number of laser treatments performed, which was slightly higher in the subthreshold micropulse laser group (mean difference 0.48, 95% confidence interval 0.18 to 0.79;p<\/jats:italic>\u2009=\u20090.002). Base-case analysis indicated no significant difference in the cost per quality-adjusted life-years between groups.<\/jats:p><\/jats:sec>Future work<\/jats:title>A trial in people with \u2265\u2009400\u2009\u00b5m diabetic macular oedema comparing anti-vascular endothelial growth factor therapy alone with anti-vascular endothelial growth factor therapy and macular laser applied at the time when central retinal subfield thickness has decreased to <\u2009400\u2009\u00b5m following anti-vascular endothelial growth factor injections would be of value because it could reduce the number of injections and, subsequently, costs and risks and inconvenience to patients.<\/jats:p><\/jats:sec>Limitations<\/jats:title>The majority of participants enrolled had poorly controlled diabetes.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Subthreshold micropulse laser was equivalent to standard threshold macular laser but required a slightly higher number of laser treatments.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>This trial is registered as EudraCT 2015-001940-12, ISRCTN17742985 and NCT03690050.<\/jats:p><\/jats:sec>Funding<\/jats:title>This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 26, No. 50. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/szki2484","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:41:54Z","timestamp":1671622914000},"page":"1-86","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn17742985","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-2937","authenticated-orcid":true,"given":"Noemi","family":"Lois","sequence":"first","affiliation":[{"name":"The Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8446-523X","authenticated-orcid":true,"given":"Christina","family":"Campbell","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit (NICTU), Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-4961","authenticated-orcid":true,"given":"Norman","family":"Waugh","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-9322","authenticated-orcid":true,"given":"Augusto","family":"Azuara-Blanco","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queens University, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2030-3338","authenticated-orcid":true,"given":"Mandy","family":"Maredza","sequence":"additional","affiliation":[{"name":"Division of Health Sciences, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-1160","authenticated-orcid":true,"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-1947","authenticated-orcid":true,"given":"Danny","family":"McAuley","sequence":"additional","affiliation":[{"name":"The Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"},{"name":"The Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-689X","authenticated-orcid":true,"given":"Nachiketa","family":"Acharya","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-7280","authenticated-orcid":true,"given":"Tariq M","family":"Aslam","sequence":"additional","affiliation":[{"name":"The Manchester Academic Health Science Centre, Manchester Royal Eye Hospital, Manchester, UK"},{"name":"Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":true,"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[{"name":"Bristol Eye Hospital, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7693-522X","authenticated-orcid":true,"given":"Victor","family":"Chong","sequence":"additional","affiliation":[{"name":"Royal Free Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-3437","authenticated-orcid":true,"given":"Louise","family":"Downey","sequence":"additional","affiliation":[{"name":"Hull and East Yorkshire Hospital, Hull and East Yorkshire NHS Trust, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-4070","authenticated-orcid":true,"given":"Haralabos","family":"Eleftheriadis","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5760-4038","authenticated-orcid":true,"given":"Samia","family":"Fatum","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-1834","authenticated-orcid":true,"given":"Sheena","family":"George","sequence":"additional","affiliation":[{"name":"Hillingdon Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-8162","authenticated-orcid":true,"given":"Faruque","family":"Ghanchi","sequence":"additional","affiliation":[{"name":"Bradford Teaching Hospitals NHS Trust, Bradford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1963-3484","authenticated-orcid":true,"given":"Markus","family":"Groppe","sequence":"additional","affiliation":[{"name":"Stoke Mandeville Hospital, Buckinghamshire NHS Trust, Aylesbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-8761","authenticated-orcid":true,"given":"Robin","family":"Hamilton","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-6564","authenticated-orcid":true,"given":"Geeta","family":"Menon","sequence":"additional","affiliation":[{"name":"Frimley Park Hospital NHS Foundation Trust, Camberley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-8001","authenticated-orcid":true,"given":"Ahmed","family":"Saad","sequence":"additional","affiliation":[{"name":"James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK"},{"name":"Zagazig University, Zagazig, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":true,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-3576","authenticated-orcid":true,"given":"Marianne","family":"Shiew","sequence":"additional","affiliation":[{"name":"Hinchingbrooke Hospital North West Anglia NHS Trust, Huntingdon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-3089","authenticated-orcid":true,"given":"David H","family":"Steel","sequence":"additional","affiliation":[{"name":"Sunderland Eye Infirmary, Sunderland, UK"},{"name":"Bioscience Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-6476","authenticated-orcid":true,"given":"James Stephen","family":"Talks","sequence":"additional","affiliation":[{"name":"Newcastle Eye Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-7052","authenticated-orcid":true,"given":"Paul","family":"Doherty","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit (NICTU), Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-7197","authenticated-orcid":true,"given":"Cl\u00edona","family":"McDowell","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit (NICTU), Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-7257","authenticated-orcid":true,"given":"Mike","family":"Clarke","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit (NICTU), Belfast, UK"},{"name":"Centre for Public Health, Queens University, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","reference":[{"key":"key20221219190646422_ref1-bib1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"key20221219190646422_ref1-bib2","unstructured":"National Institute for Health and Care Excellence (NICE). Ranibizumab for Treating Diabetic Macular Oedema. Technology Appraisal Guidance [TA274]. London: NICE; 2013. URL: www.nice.org.uk\/guidance\/ta274 (accessed 7 January 2022)."},{"key":"key20221219190646422_ref1-bib3","unstructured":"National Institute for Health and Care Excellence (NICE). Aflibercept for Treating Diabetic Macular Oedema. Technology Appraisal Guidance [TA346]. London: NICE; 2015. URL: www.nice.org.uk\/guidance\/ta346 (accessed 7 January 2022)."},{"key":"key20221219190646422_ref1-bib4","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence (NICE). Faricimab for Treating Diabetic Macular Oedema. Technology Appraisal Guidance [TA799]. London: NICE; 2022. URL: www.nice.org.uk\/guidance\/TA799 (accessed 17 November 2022).","DOI":"10.1136\/heartjnl-2022-321095"},{"key":"key20221219190646422_ref1-bib5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"key20221219190646422_ref1-bib6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ophtha.2009.10.002","article-title":"Factors associated with improvement and worsening of visual acuity 2 years after focal\/grid photocoagulation for diabetic macular edema","volume":"117","author":"Aiello","year":"2010","journal-title":"Ophthalmology"},{"key":"key20221219190646422_ref1-bib7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","article-title":"Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema","volume":"127","author":"Beck","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"key20221219190646422_ref1-bib8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"key20221219190646422_ref1-bib9","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1167\/iovs.10-6828","article-title":"Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema","volume":"52","author":"Lavinsky","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20221219190646422_ref1-bib10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/IAE.0b013e3181c96986","article-title":"Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation","volume":"30","author":"Vujosevic","year":"2010","journal-title":"Retina"},{"key":"key20221219190646422_ref1-bib11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjo.2008.146712","article-title":"Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema","volume":"93","author":"Figueira","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"key20221219190646422_ref1-bib12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1089\/pho.2010.2830","article-title":"Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography","volume":"29","author":"Venkatesh","year":"2011","journal-title":"Photomed Laser Surg"},{"key":"key20221219190646422_ref1-bib13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/eye.2010.53","article-title":"Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema","volume":"24","author":"Kumar","year":"2010","journal-title":"Eye"},{"key":"key20221219190646422_ref1-bib14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2003.040949","article-title":"Subthreshold micropulse diode laser treatment in diabetic macular oedema","volume":"88","author":"Laursen","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key20221219190646422_ref1-bib15","first-page":"2370","article-title":"Randomized, controlled clinical trial comparison of SDM laser versus argon ion laser in diabetic macular edema","volume":"13","author":"Xie","year":"2013","journal-title":"Int Eye Sci"},{"key":"key20221219190646422_ref1-bib16","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/IAE.0000000000001053","article-title":"Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials","volume":"36","author":"Chen","year":"2016","journal-title":"Retina"},{"key":"key20221219190646422_ref1-bib17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.18240\/ijo.2016.07.15","article-title":"Sub-threshold micro-pulse diode laser treatment in diabetic macular edema: a meta-analysis of randomized controlled trials","volume":"9","author":"Qiao","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"key20221219190646422_ref1-bib18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biopha.2017.10.078","article-title":"Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: a bayesian network meta-analysis","volume":"97","author":"Wu","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20221219190646422_ref1-bib19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010859.pub2","article-title":"Monotherapy laser photocoagulation for diabetic macular oedema","volume":"10","author":"Jorge","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221219190646422_ref1-bib20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.joco.2016.08.007","article-title":"Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema","volume":"28","author":"Fazel","year":"2016","journal-title":"J Curr Ophthalmol"},{"key":"key20221219190646422_ref1-bib21","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1097\/IAE.0000000000000177","article-title":"Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity","volume":"34","author":"Luttrull","year":"2014","journal-title":"Retina"},{"key":"key20221219190646422_ref1-bib22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-019-3199-5","article-title":"Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial","volume":"20","author":"Lois","year":"2019","journal-title":"Trials"},{"issue":"8","key":"key20221219190646422_ref1-bib23","doi-asserted-by":"publisher","DOI":"10.3310\/hta24080","article-title":"Plaster cast versus functional bracing for Achilles tendon rupture: the UKSTAR RCT","volume":"24","author":"Costa","year":"2020","journal-title":"Health Technol Assess"},{"key":"key20221219190646422_ref1-bib24","volume-title":"Visual Function Endpoints: The Regulatory Perspective","author":"Mosely","year":"2011"},{"key":"key20221219190646422_ref1-bib25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N Engl J Med"},{"key":"key20221219190646422_ref1-bib26","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"key20221219190646422_ref1-bib27","volume-title":"Diabetic Retinopathy Guidelines","author":"The Royal College of Ophthalmologists"},{"key":"key20221219190646422_ref1-bib28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"key20221219190646422_ref1-bib29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial","volume":"113","author":"Gillies","year":"2006","journal-title":"Ophthalmology"},{"key":"key20221219190646422_ref1-bib30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/02713680490513191","article-title":"Effect of laser photocoagulation treatment for diabetic macular oedema on patient\u2019s vision-related quality of life","volume":"29","author":"Tranos","year":"2004","journal-title":"Curr Eye Res"},{"key":"key20221219190646422_ref1-bib31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3109\/02713683.2013.781191","article-title":"Repeatability and reproducibility of retinal thickness measurements in diabetic patients with spectral domain optical coherence tomography","volume":"38","author":"Fiore","year":"2013","journal-title":"Curr Eye Res"},{"key":"key20221219190646422_ref1-bib32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-7525-11-10","article-title":"Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema","volume":"11","author":"Lloyd","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"key20221219190646422_ref1-bib33","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. Process and Methods [PMG9]. London: NICE; 2013. URL: www.nice.org.uk\/process\/pmg9 (accessed 6 September 2022)."},{"key":"key20221219190646422_ref1-bib34","volume-title":"Unit Costs of Health and Social Care 2020","author":"Curtis","year":"2020"},{"key":"key20221219190646422_ref1-bib35","volume-title":"NHS Reference Costs 2018 to 2019","author":"Department of Health and Social Care"},{"key":"key20221219190646422_ref1-bib36","unstructured":"Joint Formulary Committee. British National Formulary. 80th ed. London: BMJ Group and Pharmaceutical Press; 2022."},{"key":"key20221219190646422_ref1-bib37","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199685028.001.0001","volume-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"key20221219190646422_ref1-bib38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key20221219190646422_ref1-bib39","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"key20221219190646422_ref1-bib40","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1167\/iovs.04-1389","article-title":"Vision and quality of life: the development of a utility measure","volume":"46","author":"Misajon","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20221219190646422_ref1-bib41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/09286580801979417","article-title":"Vision and quality of life: development of methods for the VisQoL vision-related utility instrument","volume":"15","author":"Peacock","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"key20221219190646422_ref1-bib42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2288-14-75","article-title":"Tuning multiple imputation by predictive mean matching and local residual draws","volume":"14","author":"Morris","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"key20221219190646422_ref1-bib43","volume-title":"Statistical Analysis with Missing Data","author":"Little","year":"2019","edition":"3rd edn"},{"key":"key20221219190646422_ref1-bib44","volume-title":"Net Monetary Benefit.","author":"York Health Economics Consortium","year":"2016"},{"key":"key20221219190646422_ref1-bib45","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"key20221219190646422_ref1-bib46","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jama.295.10.1147","article-title":"Quality of reporting of noninferiority and equivalence randomized trials","volume":"295","author":"Le Henanff","year":"2006","journal-title":"JAMA"},{"key":"key20221219190646422_ref1-bib47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ophtha.2020.10.030","article-title":"Evaluation of a new model of care for people with complications of diabetic retinopathy: the EMERALD study","volume":"128","author":"Lois","year":"2021","journal-title":"Ophthalmology"},{"key":"key20221219190646422_ref1-bib48","volume-title":"HbA1c Calculator","author":"DiaSys"},{"key":"key20221219190646422_ref1-bib49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"key20221219190646422_ref1-bib50","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ"},{"key":"key20221219190646422_ref1-bib51","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s12325-017-0559-y","article-title":"A review of subthreshold micropulse laser for treatment of macular disorders","volume":"34","author":"Scholz","year":"2017","journal-title":"Adv Ther"},{"key":"key20221219190646422_ref1-bib52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/aos.13997","article-title":"How do we evaluate the role of focal\/grid photocoagulation in the treatment of diabetic macular edema?","volume":"97","author":"Blindb\u00e6k","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"key20221219190646422_ref1-bib53","volume-title":"Study Quality Assessment Tools","author":"National Heart, Lung, and Blood Institute"},{"key":"key20221219190646422_ref1-bib54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1442-9071.2012.02756.x","article-title":"Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema","volume":"40","author":"Casson","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"key20221219190646422_ref1-bib55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/dme.14125","article-title":"Psychological, social and everyday visual impact of diabetic macular oedema and diabetic retinopathy: a systematic review","volume":"37","author":"Cooper","year":"2020","journal-title":"Diabet Med"},{"key":"key20221219190646422_ref1-bib56","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/IAE.0000000000000521","article-title":"Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety","volume":"35","author":"Vujosevic","year":"2015","journal-title":"Retina"},{"key":"key20221219190646422_ref1-bib57","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/eye.2014.264","article-title":"Medscape. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness","volume":"28","author":"Mansouri","year":"2014","journal-title":"Eye"},{"key":"key20221219190646422_ref1-bib58","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s10103-020-02984-6","article-title":"The efficacy of selective retina therapy for diabetic macular edema based on pretreatment central foveal thickness","volume":"35","author":"Kim","year":"2020","journal-title":"Lasers Med Sci"},{"key":"key20221219190646422_ref1-bib59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10103-018-2672-9","article-title":"The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema","volume":"34","author":"Citirik","year":"2019","journal-title":"Lasers Med Sci"},{"key":"key20221219190646422_ref1-bib60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12886-018-0841-z","article-title":"Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema","volume":"18","author":"Chhablani","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"key20221219190646422_ref1-bib61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"key20221219190646422_ref1-bib62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2474126419834711","article-title":"Evidence-based guidelines for management of diabetic macular edema","volume":"3","author":"Bakri","year":"2019","journal-title":"J VitreoRetin Dis"},{"key":"key20221219190646422_ref1-bib63","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10384-021-00846-4","article-title":"Comparison of two-year treatment outcomes between subthreshold micropulse (577\u2009nm) laser and aflibercept for diabetic macular edema","volume":"65","author":"Lai","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"key20221219190646422_ref1-bib64","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"key20221219190646422_ref1-bib65","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3928\/23258160-20181203-07","article-title":"Structural integrity of individual cone photoreceptors after short-wavelength subthreshold micropulse laser therapy for diabetic macular edema","volume":"49","author":"Wells-Gray","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key20221219190646422_ref1-bib66","doi-asserted-by":"publisher","first-page":"800","DOI":"10.12968\/bjon.2017.26.14.800","article-title":"Introduction of a nurse-led intravitreal injection service in ophthalmology","volume":"26","author":"Gallagher","year":"2017","journal-title":"Br J Nurs"},{"key":"key20221219190646422_ref1-bib67","doi-asserted-by":"publisher","first-page":"e027795","DOI":"10.1136\/bmjopen-2018-027795","article-title":"Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD)","volume":"9","author":"Lois","year":"2019","journal-title":"BMJ Open"},{"issue":"32","key":"key20221219190646422_ref1-bib68","doi-asserted-by":"publisher","DOI":"10.3310\/hta25320","article-title":"Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study","volume":"25","author":"Lois","year":"2021","journal-title":"Health Technol Assess"},{"key":"key20221219190646422_ref1-bib69","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/bjophthalmol-2021-318816","article-title":"Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study","volume":"106","author":"Maredza","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"key20221219190646422_ref1-bib70","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"key20221219190646422_ref1-bib71","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20221219190646422_ref1-bib72","volume-title":"2019\/20 National Cost Collection Data Publication","author":"NHS England"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2041824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/SZKI2484\/SZKI2484.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2041824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:40:26Z","timestamp":1692114026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/SZKI2484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":72,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.3310\/SZKI2484"],"URL":"https:\/\/doi.org\/10.3310\/szki2484","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"4-2016","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"1-2022","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"5-2022","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}